Participant demographics and baseline characteristics
Between June 11, 2021 and Oct. 1, 2021, 331 people were screened and 248 were randomised (62 to mazdutide 3 mg, 63 to 4.5 mg, 61 to 6 mg and 62 to placebo). Overall, 224 participants (90.3%) completed week 24 of study treatment, while 19 (10.2%) of 186 participants with mazdutide and 5 (8.1%) of 62 with placebo discontinued the study treatment early (Fig. 